Objective: To assess long-term efficacy and tolerability of lacosamide (LCM) as adjunctive treatment through a retrospective study in children and adolescents with refractory epilepsies. Methods: All patients consecutively treated with LCM as add-on for refractory focal and generalized epilepsy and followed at the Neuroscience Center of Excellence of the Meyer Children's Hospital of Florence between January 2011 and September 2015 were included in the study. Responder rate, relapse-free survival, and retention rate were calculated. Tolerability was assessed by reporting adverse events. Results: A total of 88 individuals (41 female) aged 4 months to 18 years (median 10.5 years; mean AE SD 10.6 AE 4.8 years) received add-on LCM treatment for refractory epilepsy. Thirty-four patients (38.6%) were responders with a median time to relapse of 48 months. Nine (26.4%) of the 34 responders were seizure-free. For all 88 patients, the probability of remaining on LCM without additional therapy was 74.4% at 6 months, 47.7% at 12 months, 27.9% at 24 months, 18.0% at 48 months, and 8.2% at 72 months of follow-up. No statistically significant differences in relapse and retention time were observed with regard to epilepsy and seizure types, duration and course of epilepsy, number and type of antiepileptic drugs (AEDs; sodium channel blockers vs others) used in add-on. The most frequent adverse events were dermatological (4/11) and behavioral (3/11). Significance: This study documents a real-world progressive and significant loss of LCM efficacy over time in a pediatric population. Further prospective studies on larger populations are required to confirm the remarkable loss of LCM efficacy over time.
been fully defined, experimental evidence indicates that it selectively enhances slow inactivation of voltage-gated sodium channels, increasing the proportion of sodium channels unavailable for depolarization, thus stabilizing neuronal membranes and inhibiting sustained repetitive neuronal firing. 1 LCM has oral bioavailability of approximately 100%, and a very low plasma protein binding rate (<15%); it is eliminated by metabolic biotransformation and urinary excretion. Its drug-drug interaction profile is low and the most commonly observed adverse events (AEs) are dizziness, headache, diplopia, and nausea. 2 LCM efficacy in adults with refractory focal epilepsy was assessed in 3 double-blind randomized placebo-controlled clinical trials [3] [4] [5] and 3 phase III open-label extension trials, [6] [7] [8] while only observational studies without comparator have been conducted in the pediatric population.
Recently, McGinnis and Kessler 9 assessed LCM efficacy in a retrospective study of 233 children using drug-retention rates as outcome measure. In that study, the percentage of children remaining on LCM without addition of another drug was 44.7% at 12 months and 25.6% at 24 months. A similar study was conducted by Bottcher et al, 10 who
reported similar LCM retention rates in a mixed population of 136 patients with refractory epilepsy.
Here we report our experience with LCM as add-on therapy in a cohort of 88 children and adolescents with refractory focal and generalized epilepsy in whom longterm (72-month) efficacy and tolerability were evaluated.
| METHODS
Medical records of all patients consecutively treated with LCM as add-on for refractory focal and generalized epilepsy and followed at the Neuroscience Center of Excellence of the Meyer Children's Hospital of Florence, between January 2011 and September 2015, were screened for inclusion in the study. The last evaluation that coincides with closing time for the rating process and the start of the analysis was December 31, 2017. The study protocol and informed consent were approved by the pediatric ethics committee of the Tuscany Region on April 28, 2016. Written informed consent to the use of LCM was obtained from both parents, as in use in our Hospital for off-label drugs.
Only patients younger than 18 years of age, with a diagnosis of refractory epilepsy, as defined by the current International League Against Epilepsy (ILAE) criteria, 11 were included in the study. The manufacturer of LCM (UCB Pharma) had no involvement in the study. Drug scheme administration consisted of a starting dose of LCM of 2-3 mg/kg/d with increments every week, up to a maximum of 5-10 mg/kg/d, based on both age and weight. Information was collected about sex, age at seizure onset, age at LCM initiation, seizure type and frequency, epilepsy syndromes, epilepsy etiology, number and dosage of AEDs in add-on. Etiology of epilepsy was classified according to the ILAE classification of epilepsies 12 and codified as structural, genetic, infectious, immune, metabolic, and unknown. According to etiology, epilepsy was also considered as fixed (including genetic, with the exception of CDKL5 encephalopathy, structural as cortical malformations, infectious, and immune conditions) or progressive (including metabolic and structural as tumors). Data on LCM titration schedule, initial target dose, highest total daily dose, length of administration, reason for discontinuation, and treatment emergent AEs were also collected. Seizure frequency was recorded in a diary commonly used in our epilepsy clinic and updated at each follow-up visit, which usually takes place every 3 months or at least every 6 months, according to clinical indications. Tolerability was assessed recording type and number of AEs and the reason for drug discontinuation. Routine laboratory investigations and electroencephalographic (EEG) recordings, while awake and asleep were performed according to clinical indications. Seizure frequency at baseline was defined as the monthly number of seizures in the previous 3 months before starting LCM. Patients with a reduction of monthly seizure frequency ≥50% from baseline after reaching the target dose were considered as "responders." For patients achieving the responder status, the probability of remaining responders was then estimated. In the whole population we also calculated the retention rate and the failure-free survival as the time lag between LCM initiation to LCM failure. LCM failure was defined as either discontinuation of LCM or addition of a new AED or treatment (such as the ketogenic diet, vagus nerve stimulation, or epilepsy surgery).
| Statistical analysis
The Kaplan-Meier survival analysis was conducted to calculate relapse-free survival in responders only and the failure-free survival in the whole population. A survival analysis was also performed in relation to etiology, age at onset, seizure type, epilepsy type, and number and type of concomitant drugs. more groups was done using the log-rank test. A multivariate analysis was performed using Cox proportional hazards models. Two different models were built to estimate the hazard ratio of relapse and LCM failure outcomes for different covariates. A P-value <.05 was considered as statistically significant. All analyses were performed with the STATA version 11 software.
| RESULTS
From January 2011 to September 2015, 88 individuals (41 female) aged 4 months to 18 years (median 10.5 years; mean AE SD 10.6 AE 4.8 years) received LCM as add-on treatment for refractory focal and generalized epilepsy. Demographics and clinical data are summarized in Table 1 . Age at seizure onset ranged from 0 to 14.8 years (median 2.4 years). Median follow-up length from LCM initiation to last evaluation was 10 months (range 0-76 months). Mean AE SD LCM daily dose was 8.01 mg AE 0.75 mg/d.
Fifty-seven patients (64.7%) received LCM as add-on for refractory focal epilepsy and 13 (14.8%) for generalized epilepsy, while 18 patients (20.5%) manifested both generalized and focal seizures (combined epilepsy). Thirty-eight patients (43.2%) were taking more than 2 AEDs.
Thirty-four patients (38.6%) were responders with a median time to relapse of 48 months. Nine of the 34 responders were seizure-free (26.4%). In the 34 responders, the relapse-free survival was 94.1% at 6 months, 84.8% at 12 months, 66.8% at 36 months, and 31.3% at 72 months ( Table 2 and Figure 1) . The median time to relapse for responders with focal, generalized, and combined epilepsy was 45, 49, and 37 months, respectively. No statistically significant differences in time to relapse were observed with regard to epilepsy and seizure type, duration and course of epilepsy, and number and type of AEDs (sodium channel blockers vs others) used in add-on ( For all 88 patients, the probability of remaining on LCM with no additional treatment was 74.4% at 6 months, 47.7% at 12, 27.9% at 24, 18.0% at 48, and 8.2% at 72 months of follow-up (Table 3 and Figure 2) . No statistically significant differences in retention time were observed with regard to epilepsy and seizure types, duration and F I G U R E 1 Kaplan-Meier survival estimates for probability to remain responders course of epilepsy, and number and type of AEDs (sodium channel blockers vs others) used in add-on (Table 3) . The multivariate analysis by Cox regression showed no significant hazards of loss of responder status for exposure to different age, epilepsy type, and number and type of concomitant AEDs (Table 4a) . Similarly, the hazards of LCM discontinuation or addition of another therapy were not influenced by the same covariates, with the only exception the concomitant use of 1 or 2 AEDs that appeared to reduce the hazard of LCM discontinuation or addition of another therapy (hazard ratio [HR] 0.66; P = .087) (Table 4b) .
Adverse events were reported in 11 patients (12.5%) and led to LCM discontinuation in 10 of them. The most frequent AEs were dermatological (4/11) and behavioral (3/11).
| DISCUSSION
This study assessed the long-term efficacy of adjunctive LCM therapy in a pediatric population. Almost 40% of the 88 patients treated with LCM were responders, and only one-third of them maintained the responder status at 72 months of follow-up. When considering the retention rate, only 8% of the 88 enrolled individuals maintained the initial treatment at 72 months. Two recent studies have assessed long-term LCM efficacy in pediatric and mixed populations using the retention rate as outcome measure.
9,10 Drug-retention rate takes point out the period intervening between initiation and withdrawal of a medication, or its substitution with an alternative treatment 13 and is considered an efficacy and tolerability index. This measure, however, is a less than optimal indicator of real-world effectiveness in therapy maintenance and does not necessarily provide an indication of efficacy. The true efficacy of a drug merely measured in terms of seizure reduction might not adequately reflect if an overall clinical benefit has occurred and geographic variations in clinical practice can influence the attitude to keep or rapidly change a drug of limited efficacy. All the above factors can be heavily influenced by choices that are unrelated to the efficacy profile of a drug, which, although no more effective than previously used molecules can at times be maintained in the treatment regimen because they are better tolerated. On the contrary, our efficacy assessment method, which included both retention and a standardized measure of seizure control guarantees a more reliable efficacy measurement. For these reasons, we assessed the LCM efficacy also in terms of loss of seizure control in the 34 responders.
Comparing our study with that of McGinnins and Kessler, 9 we found a similar probability of maintaining LCM the responder rates increased over time because, according to this design, efficacy was assessed only in those individuals remaining on LCM for 1-5 years, thus did not reflect the efficacy profile of LCM in the real world. Our long-term follow-up study documents a progressive and conspicuous reduction of LCM efficacy over time. The small sample size and observational design without control are important limitations of this study. Studies with larger populations and with a prospective design are required to further elucidate the tolerance profile of LCM.
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